News
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
The stock's fall snapped a three-day winning streak.
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...
Zacks Investment Research on MSN15h
Here's Why Merck (MRK) Fell More Than Broader MarketMerck (MRK) ended the recent trading session at $80.32, demonstrating a -1.27% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.27%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback